Drugs / Ranibizumab (LUCENTUS®) [arm: active_comparator] — 0.5 mg (0.05 mL of 10 mg/mL solution) administered by intravitreal injection approximately every 28 days
Ranibizumab (LUCENTUS®) [arm: active_comparator] — 0.5 mg (0.05 mL of 10 mg/mL solution) administered by intravitreal injection approximately every 28 days
Trials 0
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT04704921 Comparator | Dec 2020 → Dec 2026 expected | choroidal neovascularization, wet macular degeneration | AbbVie | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ranibizumab (LUCENTUS) [arm: active_comparator] — 0.5 mg (0.05 mL of 10 mg/mL solution) administered by intravitreal injection approximately every 28 days | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04704921 ↗ |
| Action | Inhibit | “Ranibizumab (anti-VEGF agent)” NCT04704921 ↗ |
| Route | Intravitreal | “administered by intravitreal injection approximately every 28 days” NCT04704921 ↗ |